Stefan Johansson Posted April 21 Share Posted April 21 The SafeBoosC-III trial is now out in NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2207554) I know lots of effort has been put into this study, 70 NICUs in 17 countries included 1600 extremely preterm infants, randomised to either cerebral oximetry in the first 72 hours or usual care (without such monitoring). Primary endpoint was death or USG-diagnosed severe brain injury at 36 weeks. No differences found, the primary endpoint occured in 1/3 in both groups. How will this study impact your care? 1 1 Link to comment Share on other sites More sharing options...
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!Register a new account
Already have an account? Sign in here.Sign In Now